Pentadeca Arginat (PDA)

A pentadecapeptide sharing the amino-acid sequence of BPC-157, offered as an arginine salt for improved solubility and stability.

Pentadeca Arginate, often abbreviated PDA, carries the same 15-amino-acid sequence as the well-known peptide BPC-157. The difference lies in the counter-ion: instead of an acetate salt, the sequence is bound to arginine, which suppliers describe as improving solubility and shelf stability. Independent studies examining this specific salt form are not yet available.

Facts

Evidence

Frequently asked questions

Is Pentadeca Arginate the same as BPC-157?
The amino-acid sequence is identical. The difference lies in the counter-ion: BPC-157 is usually offered as an acetate salt, Pentadeca Arginate as an arginine salt, which suppliers describe as improving solubility.

Are there independent studies on the arginine salt form?
No, a targeted literature search found no independent studies on the arginine salt form itself. The available evidence relates to the BPC-157 parent sequence.

Is Pentadeca Arginate an approved medication?
No. It is not approved in the EU or the United States and is sold exclusively as a research chemical for laboratory use.

Documented prices

List prices excluding shipping and discounts. Currency and product variants must be compared separately. Availability and delivered batch have not been verified.

No comparable documented prices are available.

← Back to Peptides